4.27%XLF 16.00 10.11%QQQQ 32.65 6.34%
The Global Business News Leader | Tuesday, 7 Oct 2008
- EQUITY MARKETS
- BONDS AND RATES
- FOREX
- COMMODITIES
- LANGUAGES
- FUNDS
- RETIREMENT
- TAXES
- INSURANCE
- LANGUAGES
- MOVIE
- MUSIC
- TV
- CELEBRITIES
- LANGUAGES
ARENA PHARMACEUTIC
ARNA (NASDAQ)
$ 4.08 
Change: -0.29 -7.11% | Volume: 1,191,638
Change: -0.29 -7.11% | Volume: 1,191,638
ARENA PHARMA - Fundamental Profile
Company Information
| Ticker Symbol: | ARNA |
|---|---|
| Exchange: | NASD |
| Contact Info: | 6166 Nancy Ridge Drive San Diego CA 92121 858 453-7200 |
| CEO/President: | Jack Lief |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena\'s most advanced product candidate, lorcaserin, is being investigated in a Phase three clinical trial program for the treatment of obesity. Arena\'s broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc. |
Share Information
| Shares Outstanding: | 73,840 (000) | Market Value: | 332,790 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 88.21% | Number of Inst.Shareholders: | 4.10% |
| Last Quarter Sales: | 2.64 ($Mil.) | Last Quarter Net Income: | -65.27 ($Mil.) |
| Last Quarter EPS: | -0.89 | P/E Ratio: | 0 |
| Most Recent Earnings: | -0.89 on 08/05/08 | Earnings Per Share: | -2.78 |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |
Data Provided By Barchart.com
CoreData does not represent, warrant, or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever to any party on account of any incompleteness of, inaccuracies in or untimeliness of the CoreData content provided hereunder, or for any delay in reporting such data. CoreData expressly disclaims all warranties of fitness of the CoreData content or computations and analyses thereof for a particular purpose or use.
Top Competitors
| AMGEN |  |
+14.00 | 58.89 |
| GILEAD SCIENCES |  |
-0.20 | 45.75 |
| GENENTECH INC | |
+16.10 | 87.53 |
| CELGENE CP | |
-14.40 | 60.46 |
| BIOGEN IDEC INC | |
-16.30 | 50.50 |
Partners  
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives